Background Evidence suggests a role for excessive inflammation in COVID-19 complications.
Colchicine is an oral anti-inflammatory medication beneficial in gout, pericarditis, and …

Background Evidence suggests the role of an inflammatory storm in COVID-19 complications.
Colchicine is an orally administered, anti-inflammatory medication beneficial in gout, …

Randomized controlled trials (RCTs) remain the gold standard to evaluate clinical interventions,
producing the highest level of evidence while minimizing potential bias. Inadequate …

We conducted a genome-wide association study of time to remission of COVID-19 symptoms
in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA …

OBJECTIVE The cardiovascular benefits of low-dose colchicine have been demonstrated in
patients with coronary disease. Its effects were evaluated in this prespecified analysis in …

We conducted a genome-wide association study of time to remission of COVID-19 symptoms
in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA …

Background Access to pacemakers and defibrillators is problematic in places with limited
resources. Resterilization and reuse of implantable cardiac devices obtained post mortem from …

Inflammation is widely believed to play a central role in the pathogenesis of atherosclerosis
and acute coronary events. 1, 2 Although treatments with proven benefits for secondary …

Aims The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits
of targeting inflammation after myocardial infarction (MI). We aimed to determine whether …

Aims In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular
events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. The dal…